British Researchers Report Extended Mesothelioma Survival with New Drug, According to Surviving Mesothelioma

Share Article

Scientists in Surrey and London say two peritoneal mesothelioma patients are still living 10 and 13 years after their diagnosis.

Mesothelioma Survival with Apitolisib

Improving Mesothelioma Survivability

Both patients obtained symptomatic and disease benefit with apitolisib...

Doctors with the Royal Marsden NHS Foundation Trust and the Institute of Cancer Research are reporting long-term survival of peritoneal mesothelioma with a drug called apitolisib. Surviving Mesothelioma has the full story. Click here to read it now.

The two peritoneal mesothelioma patients whose cases are detailed in the report both relapsed after standard chemotherapy and were given apitolisib, a drug designed to inhibit certain cell signaling pathways.

“Both patients obtained symptomatic and disease benefit with apitolisib...with one patient having a partial response for almost 3 years,” writes lead author Saoirse Dolly with the Royal Marsden NHS Foundation Trust. “Both are alive and well 10-13 years from diagnosis.”

The report, published in the online-only open access medical journal ESMO Open, concludes that certain patients with a slow-growing form of peritoneal mesothelioma could benefit from the treatment and should be recruited for clinical trials.

“Given the limitations of standard pemetrexed-based chemotherapy for mesothelioma, we are excited about the possibilities for apitolisib and will be tracking its progress closely,” says Alex Strauss, Managing Editor for Surviving Mesothelioma.

To read more about how apitolisib works and about long-term survival of peritoneal mesothelioma, see Long-Term Peritoneal Mesothelioma Survival with Apitolisib, now available on the Surviving Mesothelioma website.

Dolly, S, et al, “Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy”, April 12, 2017, ESMO Open, eCollection 2017, http://esmoopen.bmj.com/content/2/1/e000101

For more than a decade, Surviving Mesothelioma has brought readers the most important and ground-breaking news on the causes, diagnosis and treatment of mesothelioma. All Surviving Mesothelioma news is gathered and reported directly from the peer-reviewed medical literature. Written for patients and their loved ones, Surviving Mesothelioma news helps families make more informed decisions.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Michael Ellis
Cancer Monthy
+1 (919) 570-8595
Email >
Follow us on
Visit website